Urapidil

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Urapidil
Accession Number
DB12661
Type
Small Molecule
Groups
Investigational
Description

Urapidil has been investigated for the treatment of Hypertension During Pre-Eclampsia.

Structure
Thumb
3D
Similar Structures
Synonyms
Not Available
Categories
UNII
A78GF17HJS
CAS number
34661-75-1
Weight
Average: 387.484
Monoisotopic: 387.227039814
Chemical Formula
C20H29N5O3
InChI Key
ICMGLRUYEQNHPF-UHFFFAOYSA-N
InChI
InChI=1S/C20H29N5O3/c1-22-18(15-19(26)23(2)20(22)27)21-9-6-10-24-11-13-25(14-12-24)16-7-4-5-8-17(16)28-3/h4-5,7-8,15,21H,6,9-14H2,1-3H3
IUPAC Name
6-({3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl}amino)-1,3-dimethyl-1,2,3,4-tetrahydropyrimidine-2,4-dione
SMILES
COC1=CC=CC=C1N1CCN(CCCNC2=CC(=O)N(C)C(=O)N2C)CC1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Unlock Additional Data
(R)-warfarinThe risk or severity of adverse effects can be increased when Urapidil is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of adverse effects can be increased when Urapidil is combined with (S)-Warfarin.
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid may decrease the antihypertensive activities of Urapidil.
1-benzylimidazoleThe risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Urapidil.
2,5-Dimethoxy-4-ethylamphetamineThe therapeutic efficacy of Urapidil can be decreased when used in combination with 2,5-Dimethoxy-4-ethylamphetamine.
2,5-Dimethoxy-4-ethylthioamphetamineThe therapeutic efficacy of Urapidil can be decreased when used in combination with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamineThe therapeutic efficacy of Urapidil can be decreased when used in combination with 4-Bromo-2,5-dimethoxyamphetamine.
4-Bromo-2,5-dimethoxyphenethylamineThe therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Urapidil.
4-hydroxycoumarinThe risk or severity of adverse effects can be increased when Urapidil is combined with 4-hydroxycoumarin.
4-MethoxyamphetamineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Urapidil.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
5639
PubChem Substance
347828865
ChemSpider
5437
ChEBI
32278
ChEMBL
CHEMBL279229
Wikipedia
Urapidil
ATC Codes
C02CA06 — Urapidil

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingTreatmentAortic Dissection Type B / High Blood Pressure (Hypertension)1
3Active Not RecruitingTreatmentHigh Blood Pressure (Hypertension) / Preeclampsia1
3Unknown StatusTreatmentHypertension During Pre-Eclampsia1
4RecruitingTreatmentNontraumatic Intracerebral Hemorrhage, Multiple Localized1
Not AvailableCompletedTreatmentCerebral Hemorrhage / Cerebrovascular Accident / Intracranial Hemorrhages1
Not AvailableCompletedTreatmentScheduled Laparoscopic Surgery1
Not AvailableRecruitingDiagnosticGeneral Surgery1
Not AvailableRecruitingTreatmentAging / Anaesthesia therapy / Blood Loss,Surgical / Blood Pressures / General Surgery / Postoperative Delirium1
Not AvailableWithdrawnTreatmentIschemia, Cerebral1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.541 mg/mLALOGPS
logP1.69ALOGPS
logP1.18ChemAxon
logS-2.9ALOGPS
pKa (Strongest Basic)8.11ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area68.36 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity119.37 m3·mol-1ChemAxon
Polarizability43.07 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-0439000000-1f066af9035f53bb2d89
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-0900000000-2ccc838e7c2c252cb8ad

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
Phenylpiperazines
Alternative Parents
N-arylpiperazines / Aminophenyl ethers / Methoxyanilines / Anisoles / Dialkylarylamines / Methoxybenzenes / Phenoxy compounds / N-alkylpiperazines / Aminopyrimidines and derivatives / Alkyl aryl ethers
show 12 more
Substituents
Phenylpiperazine / N-arylpiperazine / Aminophenyl ether / Methoxyaniline / Tertiary aliphatic/aromatic amine / Phenoxy compound / Anisole / Dialkylarylamine / Aniline or substituted anilines / Phenol ether
show 28 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 17:31 / Updated on December 02, 2019 09:30